Immunowake employs innovative bi-specific platforms to enhance the immune response against tumors. Their CD3 Bi-specific Platform allows for the rapid generation of bi-specific antibodies that can activate T-cells in an antigen-dependent manner, effectively targeting cancer cells. Additionally, the VEGF Trap Platform is designed to neutralize the immunosuppressive effects of proteins secreted by tumors, such as TGF-β and VEGF. By combining checkpoint inhibitors with these traps, Immunowake aims to improve therapeutic potency and reduce adverse side effects associated with traditional immunotherapy.

The company's Y-traps and VEGF-traps serve as bifunctional fusion proteins that target critical pathways in cancer progression. The Y-traps target checkpoint inhibitors like CTLA-4 and PD-1/PD-L1, while the VEGF-traps focus on vascular endothelial growth factor, a key mediator of angiogenesis in tumors. Clinical studies have demonstrated the efficacy of these approaches, showing that combination therapies can significantly enhance response rates and reduce disease progression. Immunowake's development of the PD-L1/VEGF trap has shown promising results in animal studies, indicating potential for long-term tumor regression and the generation of anti-tumor memory, which could lead to more effective cancer treatments.

United States

Immunowake focuses on identifying new therapies for patients who do not respond to existing treatments. Our strategy involves harnessing the body’s immune system to identify and kill cancer cells the same way pathogens are identified and targeted. Recent breakthroughs in cancer immunotherapy have demonstrated that powerful anti-tumor responses can be achieved by activating antigen specific T-cells.

Immunowake

Company Details